Global Stelara Injections Market
Stelara Injections Market (Product Type: Originator Ustekinumab and Ustekinumab Biosimilars; Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis and Others; Formulation: Intravenous (IV) and Subcutaneous (SC); Dosage Strength: 45 mg, 90 mg and 130 mg IV; End-user: Hospitals, Specialty Clinics, Infusion Centers and Others; Distribution: Retail Pharmacies and Online) – Global Industry Analysis, Shares, Growth, Trends and Forecast 2021-2036
Categories:
All, Healthcare and Life Sciences
| Format: PDF/PPT/Excel
| Product ID:
4566
| Report Version:
June 2026
Market Snappshot
- Market Size in 2025: $US 11.23 Bn
- Forecast Market by 2036: $US 19.4 Bn
- CAGR for the Period 2026-2036: 5.4%
- Top Region in Terms of Market Share: North America (48.3%)
- Key Players: Johnson & Johnson, Amgen, Alvotech, Teva Pharmaceutical Industries, Samsung Bioepis, Sandoz, Celltrion, Biocon Biologics, Fresenius Kabi, and Others
Analyst Viewpoint:
The Stelara Injections Market is expected to experience a substantial shift in growth trajectory. The entry of alternative biologic therapeutics and biosimilar products into the market may pressure providers to seek cheaper alternatives for the treatment of these complex autoimmune diseases. A growing patient population experiencing the effects of the increasing prevalence of inflammatory diseases i.e. almost 1-3% globally have plaque psoriasis and >10 million people worldwide suffer from an inflammatory bowel disease like ulcerative colitis or Crohn’s, that necessitates long-term management further supports the sustained demand of these products. The larger Autoimmune Disease Biologics Market also grows due to the growing demand for the administration of specific target biologic molecules like monoclonal antibodies, which dominates the world biologic market. Modern developments in biologic processes and technologies have enabled companies to manufacture more effective products and increase their productivity, scale and also reduced disruptions. The participating companies, also, form key alliances, aim to penetrate newer markets, and extend their biologic product portfolios. As Ustekinumab biosimilar products are introduced to the market and may cut down as much as 20-40% on medical treatment costs as opposed to its original biologics counterpart, the new Ustekinumab Biosimilars Market. These factors also create many of the industry’s obstacles like restrictive rules, challenging manufacturing processes, and the entrance of other new immunology treatment products.
Stelara Injections Market Overview:
The Ustekinumab Market includes all research, production, and commercialization activities involving biological therapeutics built on Ustekinumab, a monoclonal antibody which works by targeting the signaling of interleukin-12 and interleukin-23. Through its regulation of these major pro-inflammatory mediators, the therapeutic has emerged as a gold standard treatment for a variety of chronic, immune-mediated diseases and remains a key element in today’s immunology therapy armamentarium. The Ustekinumab Market constitutes a vital component of the IL-12/23 Inhibitor Market and has gained significant usage for patients diagnosed with psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Physician confidence in the use of the drug is bolstered by clinical data showing the ability to clear over 70% of qualifying patients for plaque psoriasis therapy with a biologic, while both intravenous induction and subcutaneous maintenance regimens afford treatment versatility and enhance adherence. Production demands require specialized biotechnology using recombinant mammalian cell culture systems; multi-stage purification steps; and temperature-controlled distribution channels, making the research and development costs for biologics high and increasing barriers to market entry. Moreover, the market is receiving a boost from growth within the Psoriasis Biologics Market where biologics comprise more than half of the revenues in moderate to severe psoriasis treatment across developed markets. Additionally, the launch of biosimilar therapeutics has improved affordability for patients and practitioners and ongoing advancements in analytical testing, manufacturing processes and production efficiencies continue to drive market growth for biologics overall.
| Drivers | Rising Prevalence of Autoimmune Diseases Expanding Biologics Demand |
| Biosimilar Penetration Improving Access to Ustekinumab Therapies |
Rising Prevalence of Autoimmune Diseases Expanding Biologics Demand
The increase in the incidence of autoimmune and inflammatory diseases is the main growth factor for the Stelara Injections Market. Urbanization, environmental factors, genetic predisposition, and the improvement of screening are the leading factors attributed to the growing number of patients who need prolonged therapy. Approximately 4-5% of the world’s population suffers from autoimmune diseases; hence the demand is higher than supply for modern biologic drugs, supporting growth across the overall Autoimmune Disease Biologics Market. Psoriasis Biologics Market, around 20-30% of all psoriasis patients also develop psoriatic arthritis, creating further demand for specific biologic drugs that manage both the disease conditions. Inflammatory bowel diseases continue to be on the rise globally, and over 7 million cases have been identified so far across the globe, leading to growth across both the Crohn’s Disease Biologics Market and Ulcerative Colitis Biologics Market. Within the Ustekinumab Market, Ustekinumab is one of the leading biologic therapies for its selective cytokine inhibition that manages the signs and symptoms of disease, and enhances quality of life. Biologics offer significant advantages to healthcare systems due to their impact on reducing the development of complications related to disease and improving clinical outcomes over the long term. Currently, biologic therapies contribute almost 40% of expenditure on specialty medicines across various developed markets. Coupled with better reimbursement scenarios and widespread adoption among physicians, the Ustekinumab Injection Market is anticipated to register continued growth during the projected span.
Biosimilar Penetration Improving Access to Ustekinumab Therapies
The growing Ustekinumab Biosimilars Market presents a massive opportunity in the Global Stelara Injections Market due to increasing number of patent expirations and increased patient access to affordable treatment options. Industry reports estimate the global saving with the help of biosimilars in 2024 to be over USD 20 billion and this is estimated to increase significantly with introduction of Ustekinumab biosimilars in both developed and developing markets which would increase access to treatment. Increased process efficiency due to technological developments like cell-culture optimization, process intensification, process control, improved analytical characterization, and quality-control has reduced biosimilar development timeline by 30% in the recent generation. Due to the improved manufacturing and regulatory science within Injectable Biologics Market, efficiency of producing a biosimilar is at a high as compared to earlier generations, therefore enhancing the competitiveness in Injectable Biologics Market along with enhanced quality of products. The major pharmaceutical markets have efficient regulatory pathways established that approve biosimilars and thereby encourages investment & rapid commercialization of these biosimilars. From a commercial perspective, the price difference at the time of biosimilar launch is 15-35%, thus leading to better patient access & reduced burden for payer. As physician confidence in prescribing biosimilars grows, there is increased treatment penetration in Ustekinumab Market. Increased opportunity in Ustekinumab Biosimilars Market leads to increase in IL-12/23 Inhibitor Market and increased global treatment access.
Stelara Injections Regional Market Outlook:
North America leads the global Stelara Injections Market, contributing nearly 48.3% to overall revenues. The region’s strong adoption of biologics, favorable reimbursement environment, sophisticated specialty healthcare facilities, and well-established awareness on treatment of autoimmune disorders are contributing factors. The United States alone dominates the Ustekinumab Market as well as Autoimmune Disease Biologics Market and plays a critical commercial role in the launch of biosimilar products. Europe emerges as the second-leading market with nearly 27.5% of global revenues owing to increased uptake within the Ustekinumab Biosimilars Market and a wide healthcare network across Germany, France, the UK, Spain, and Italy. The Asia Pacific region constitutes nearly 17.0% of the global market revenues and is expected to grow at the fastest pace during the forecast period. Major countries in this region such as China, Japan, South Korea, Australia and India, are significantly expanding their biologics manufacturing capabilities to improve healthcare access in Psoriasis Biologics Market, Crohn’s Disease Biologics Market and Ulcerative Colitis Biologics Market. The Latin American and Middle Eastern & African regions contribute around 4.2% and 3.0% of the market revenue, respectively. Both regions are witnessing positive trends such as healthcare modernization initiatives, expansion of the biologic reimbursement system, and increasing access to advanced therapies within the Injectable Biologics Market globally.
Key Companies in Stelara Injections Market:
The Ustekinumab market is becoming more competitive with biosimilar producers scaling up their marketing activities in the major health economies. Historically, the original branded product held the lion share of the market but new entrants with products that offer a broader competitive profile and price competition is gaining momentum. The major market players are investing heavily in their manufacturing capacity, seeking regulatory approvals, improving supply chain performance and are seeking strategic collaborations to increase market share. Advances in biological production technologies and ability to market globally are still major differentiators in terms of market share. Competitive pressure will be intensified as the usage increases across the Ulcerative Colitis Biologics market and the others segments. Key Players include Johnson & Johnson, Amgen, Alvotech, Teva Pharmaceutical Industries, Samsung Bioepis, Sandoz, Celltrion, Biocon Biologics, Fresenius Kabi, Formycon AG, Bio-Thera Solutions, Shanghai Henlius Biotech, Dong-A ST, CuraTeQ Biologics and Others.
Key Developments in Stelara Injections Market:
| 1. Johnson & Johnson Announces FDA Approval of STELARA® for Pediatric Crohn’s Disease: In April 2026, the U.S. Food and Drug Administration (FDA) approved STELARA®(Ustekinumab) for the treatment of patients two years and older with moderately to severely active Crohn’s disease |
| 2. Amgen Introduces WEZLANA in the United States: In January 2025, In January 2025, Amgen launched WEZLANA, an interchangeable biosimilar version of Ustekinumab, enhancing treatment accessibility and strengthening competition within the global biologics sector. |
Stelara Injections Market Attributes:
| ATTRIBUTE | DETAILS |
| Market Value, 2025 | $US 11.23 Billion |
| Forecasted Market Value, 2036 | $US 19.4 Billion |
| CAGR (2026-2036) | 5.4% |
| Analysis Period | 2021-2036 |
| Historic Period | 2021-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2036 |
| Volume Unit | Thousand Doses |
| Value Unit | $US Billion |
| Market Segmentation | By Product Type
By Indication
By Formulation
By Dosage Strength
By End-user
By Distribution
By Region
|
| Companies Profiles |
|
| Customization Request | Available upon request |
1. Introduction
1.1. Report Scope
1.2. Market Segmentations and Definitions
1.3. Geographical Coverage
2. Executive Summary
2.1. Key Facts and Figures
2.2. Trends Impacting the Market
2.3. DatasticsR Growth Opportunity Matrix
3. Market Overview
3.1. Global Stelara Injections Market Analysis and Forecast, 2021-2036
3.1.1. Global Stelara Injections Market Size ($US Bn)
3.1.2. Global Stelara Injections Market Size (Thousand Doses)
3.2. Supply-side and Demand-side Trends
3.3. Technology Roadmap and Developments
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Porter’s Five Forces Analysis
3.6. PESTL Analysis
3.7. Industry SWOT Analysis
3.8. Regulatory Landscape
3.9. Value Chain Analysis
3.9.1. List of Biologics (Raw Material) Suppliers
3.9.2. List of Drug Manufacturers
3.9.3. List of Packaging Companies
3.9.4. List of Contract Manufacturers
3.9.5. List of Distributors
3.9.6. List of Potential Customers
3.10. Impact of Current Geopolitical Scenario on the Market
4. Technical Analysis
4.1. Drug Specification/Formulation Analysis
4.2. Details of Production Process
4.3. Technology Adoption and Emerging Technologies
4.4. R&D Trends and Patents Landscape
4.5. Cost Structure and Profitability Analysis
5. Global Stelara Injections Production (Thousand Doses), by region, 2025
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Latin America
5.5. Middle East and Africa
6. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
7. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
8. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
9. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
10. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
11. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
12. Global Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Region, 2021-2036
13. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
14. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
15. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
16. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
17. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
18. North America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
19. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
20. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
21. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
22. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
23. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
24. U.S. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
25. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
26. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
27. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
28. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
29. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
30. Canada Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
31. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
32. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
33. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
34. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
35. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
36. Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
37. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
38. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
39. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
40. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
41. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
42. Germany Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
43. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
44. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
45. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
46. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
47. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
48. U.K. Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
49. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
50. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
51. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
52. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
53. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
54. France Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
55. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
56. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
57. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
58. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
59. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
60. Italy Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
61. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
62. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
63. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
64. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
65. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
66. Spain Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
67. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
68. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
69. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
70. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
71. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
72. Russia & CIS Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
73. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
74. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
75. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
76. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
77. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
78. Rest of Europe Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
79. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
80. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
81. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
82. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
83. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
84. Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
85. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
86. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
87. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
88. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
89. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
90. China Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
91. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
92. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
93. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
94. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
95. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
96. India Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
97. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
98. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
99. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
100. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
101. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
102. Japan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
103. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
104. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
105. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
106. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
107. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
108. South Korea Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
109. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
110. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
111. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
112. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
113. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
114. Taiwan Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
115. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
116. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
117. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
118. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
119. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
120. Australia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
121. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
122. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
123. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
124. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
125. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
126. ASEAN Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
127. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
128. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
129. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
130. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
131. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
132. Rest of Asia Pacific Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
133. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
134. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
135. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
136. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
137. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
138. Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
139. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
140. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
141. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
142. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
143. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
144. Brazil Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
145. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
146. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
147. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
148. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
149. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
150. Mexico Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
151. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
152. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
153. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
154. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
155. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
156. Argentina Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
157. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
158. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
159. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
160. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
161. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
162. Rest of Latin America Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
163. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
164. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
165. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
166. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
167. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
168. Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
169. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
170. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
171. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
172. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
173. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
174. Saudi Arabia Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
175. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
176. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
177. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
178. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
179. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
180. UAE Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
181. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
182. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
183. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
184. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
185. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
186. South Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
187. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Product Type, 2021-2036
188. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Indication, 2021-2036
189. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Formulation, 2021-2036
190. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Dosage Strength, 2021-2036
191. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by End-user, 2021-2036
192. Rest of Middle East & Africa Stelara Injections Market Analysis and Forecasting (Thousand Doses) ($US Bn), by Distribution, 2021-2036
193. Competition Landscape
193.1. Market Share Analysis (%), by Company, 2025
193.2. Competitive Benchmarking
193.3. Company Profiles
193.3.1. Johnson & Johnson
193.3.1.1. Company Overview
193.3.1.2. Business Portfolio
193.3.1.3. Financials
193.3.1.4. Geographical Footprint
193.3.1.5. SWOT Analysis
193.3.1.6. Recent Developments and Strategies
193.3.2. Amgen
193.3.2.1. Company Overview
193.3.2.2. Business Portfolio
193.3.2.3. Financials
193.3.2.4. Geographical Footprint
193.3.2.5. SWOT Analysis
193.3.2.6. Recent Developments and Strategies
193.3.3. Alvotech
193.3.3.1. Company Overview
193.3.3.2. Business Portfolio
193.3.3.3. Financials
193.3.3.4. Geographical Footprint
193.3.3.5. SWOT Analysis
193.3.3.6. Recent Developments and Strategies
193.3.4. Teva Pharmaceutical Industries
193.3.4.1. Company Overview
193.3.4.2. Business Portfolio
193.3.4.3. Financials
193.3.4.4. Geographical Footprint
193.3.4.5. SWOT Analysis
193.3.4.6. Recent Developments and Strategies
193.3.5. Samsung Bioepis
193.3.5.1. Company Overview
193.3.5.2. Business Portfolio
193.3.5.3. Financials
193.3.5.4. Geographical Footprint
193.3.5.5. SWOT Analysis
193.3.5.6. Recent Developments and Strategies
193.3.6. Sandoz
193.3.6.1. Company Overview
193.3.6.2. Business Portfolio
193.3.6.3. Financials
193.3.6.4. Geographical Footprint
193.3.6.5. SWOT Analysis
193.3.6.6. Recent Developments and Strategies
193.3.7. Celltrion
193.3.7.1. Company Overview
193.3.7.2. Business Portfolio
193.3.7.3. Financials
193.3.7.4. Geographical Footprint
193.3.7.5. SWOT Analysis
193.3.7.6. Recent Developments and Strategies
193.3.8. Biocon Biologics
193.3.8.1. Company Overview
193.3.8.2. Business Portfolio
193.3.8.3. Financials
193.3.8.4. Geographical Footprint
193.3.8.5. SWOT Analysis
193.3.8.6. Recent Developments and Strategies
193.3.9. Fresenius Kabi
193.3.9.1. Company Overview
193.3.9.2. Business Portfolio
193.3.9.3. Financials
193.3.9.4. Geographical Footprint
193.3.9.5. SWOT Analysis
193.3.9.6. Recent Developments and Strategies
193.3.10. Formycon AG
193.3.10.1. Company Overview
193.3.10.2. Business Portfolio
193.3.10.3. Financials
193.3.10.4. Geographical Footprint
193.3.10.5. SWOT Analysis
193.3.10.6. Recent Developments and Strategies
193.3.11. Bio-Thera Solutions
193.3.11.1. Company Overview
193.3.11.2. Product Portfolio
193.3.11.3. Financials
193.3.11.4. Geographical Footprint
193.3.11.5. SWOT Analysis
193.3.11.6. Recent Developments and Strategies
193.3.12. Shanghai Henlius Biotech
193.3.12.1. Company Overview
193.3.12.2. Business Portfolio
193.3.12.3. Financials
193.3.12.4. Geographical Footprint
193.3.12.5. SWOT Analysis
193.3.12.6. Recent Developments and Strategies
193.3.13. Dong-A ST
193.3.13.1. Company Overview
193.3.13.2. Business Portfolio
193.3.13.3. Financials
193.3.13.4. Geographical Footprint
193.3.13.5. SWOT Analysis
193.3.13.6. Recent Developments and Strategies
193.3.14. CuraTeQ Biologics
193.3.14.1. Company Overview
193.3.14.2. Business Portfolio
193.3.14.3. Financials
193.3.14.4. Geographical Footprint
193.3.14.5. SWOT Analysis
193.3.14.6. Recent Developments and Strategies
193.3.15. Others
194. Appendix
- Get Started -
Get insights that lead to new growth opportunities
- Talk to Experts -
Get answers to your queries on this report from our experts
Frequently Asked Questions
The global Stelara Injections market in 2025 was $US 11.23 Billion.
The global Stelara Injections market will be $US 19.4 Billion by 2036.
The expected growth rate (CAGR%) of the global Stelara Injections market is 5.4% for the period 2026-2036.
Rising Prevalence of Autoimmune Diseases Expanding Biologics Demand and Biosimilar Penetration Improving Access to Ustekinumab Therapies.
In terms of indication Plaque Psoriasis was the largest segment holding close to 40% share among all in Stelara Injections Market in 2025.
North America was the leading regions for Stelara Injections holding 48.3% of the global market in 2025.
Johnson & Johnson, Amgen, Alvotech, Teva Pharmaceutical Industries, Samsung Bioepis, Sandoz, Celltrion, Biocon Biologics, Fresenius Kabi, Formycon AG, Bio-Thera Solutions, Shanghai Henlius Biotech, Dong-A ST, CuraTeQ Biologics and Others.
